David Rosner, Navin Joneja, Joshua Krane, Sep 30, 2013
The Canadian Competition Bureau, pharmaceutical companies operating in Canada, and Canadian lawyers have been following the U.S. Supreme Court proceedings in FTC v. Actavis, Inc. et al. with some interest. In its June 2013 decision, the Court ruled on how so-called “reverse payments” by originator pharmaceutical companies to generic pharmaceutical companies in settlement of patent infringement litigation will be assessed under U
...THIS ARTICLE IS NOT AVAILABLE FOR IP ADDRESS 3.12.162.179
Please verify email or join us to access premium content!